Related Experiment Video
Updated: Sep 23, 2025

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
The role of histone deacetylase 3 in breast cancer
Rezgar Rahbari1, Yousef Rasmi1, Mohammad Hassan Khadem-Ansari2
1Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Abstract:
It has been recently revealed that Histone Deacetylase (HDAC) 3, a unique member of the HDACs family, can trigger and progress cancers by alternation in genes expression and proteins activity. Epigenetic modifications by HDACs have been studied well in various cancer cells. Recent studies have focused on the HDAC enzymes as a possible target in cancer therapy. There are significant documents on upregulation of HDAC3 in breast cancer (BC) cells which suggest an oncogenic role for this enzyme. Interestingly, some studies showed that HDAC3 inhibition could be considered as a promising target in breast cancer therapy, and thus far, several inhibitors from different nature have been introduced. In this review, we discussed the function and highlight the existing inhibitors of HDAC3 in BC pathogenesis and therapy.
Insights
Histone Deacetylase (HDAC) 3 plays a role in cancer progression by altering gene expression. Inhibiting HDAC3 shows promise as a therapeutic strategy for breast cancer (BC).
Area of Science:
- Molecular Biology
- Oncology
- Epigenetics
Background:
- Histone Deacetylase (HDAC) 3 is implicated in cancer development through gene expression and protein activity modulation.
- HDAC enzymes are increasingly recognized as potential therapeutic targets in oncology.
- Upregulation of HDAC3 in breast cancer (BC) suggests its oncogenic role.
Purpose of the Study:
- To review the function of HDAC3 in breast cancer pathogenesis.
- To highlight current HDAC3 inhibitors for breast cancer therapy.
Main Methods:
- Literature review of studies on HDAC3 in breast cancer.
- Analysis of HDAC3's role in gene regulation and protein activity.
- Survey of existing HDAC3 inhibitors and their therapeutic potential.
Main Results:
- HDAC3 contributes to cancer progression by affecting gene expression.
- HDAC3 inhibition is a promising therapeutic avenue for breast cancer.
- Various HDAC3 inhibitors have been developed.
Conclusions:
- HDAC3 is a significant factor in breast cancer development and progression.
- Targeting HDAC3 offers a viable therapeutic strategy for breast cancer patients.
- Further research into HDAC3 inhibitors is warranted for effective breast cancer treatment.
Related Concept Videos
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Spreading of Chromatin Modifications
Writers
The writer...
Histone Variants at the Centromere
Inheritance of Chromatin Structures
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...

